DK2275439T3 - Hidtil ukendte insulinderivater - Google Patents

Hidtil ukendte insulinderivater

Info

Publication number
DK2275439T3
DK2275439T3 DK10174494.4T DK10174494T DK2275439T3 DK 2275439 T3 DK2275439 T3 DK 2275439T3 DK 10174494 T DK10174494 T DK 10174494T DK 2275439 T3 DK2275439 T3 DK 2275439T3
Authority
DK
Denmark
Prior art keywords
insulin derivatives
hitherto unknown
unknown insulin
hitherto
derivatives
Prior art date
Application number
DK10174494.4T
Other languages
English (en)
Inventor
Ib Jonassen
Thomas Hoeg-Jensen
Svend Havelund
Tina M Ller Tagmose
Ulla Ribel-Madsen
Peter Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36947523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2275439(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from EP04739008A external-priority patent/EP1660531A2/en
Application granted granted Critical
Publication of DK2275439T3 publication Critical patent/DK2275439T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK10174494.4T 2003-08-05 2004-07-22 Hidtil ukendte insulinderivater DK2275439T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (1)

Publication Number Publication Date
DK2275439T3 true DK2275439T3 (da) 2014-05-12

Family

ID=36947523

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09165072.1T DK2107069T3 (da) 2003-08-05 2004-07-22 Nye insulinderivater
DK10174494.4T DK2275439T3 (da) 2003-08-05 2004-07-22 Hidtil ukendte insulinderivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09165072.1T DK2107069T3 (da) 2003-08-05 2004-07-22 Nye insulinderivater

Country Status (10)

Country Link
EP (3) EP2264066A3 (da)
KR (1) KR101186851B1 (da)
CN (2) CN101955527B (da)
DK (2) DK2107069T3 (da)
ES (2) ES2472421T3 (da)
PL (1) PL2275439T3 (da)
PT (2) PT2275439E (da)
RU (1) RU2352581C2 (da)
SI (1) SI2107069T1 (da)
ZA (1) ZA200600846B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2107069T3 (pl) 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CA2795091A1 (en) * 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
US20130261051A1 (en) * 2010-10-27 2013-10-03 Thue Johansen Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
AU2012350586B2 (en) * 2011-12-15 2017-02-02 Jiangsu Hengrui Medicine Co., Ltd. Human insulin analogue and acylated derivative thereof
WO2013164375A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
US20160296602A1 (en) * 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
CN103467594A (zh) * 2013-09-12 2013-12-25 深圳先进技术研究院 胰岛素修饰物及其制备方法和应用
CN105001140B (zh) * 2015-06-29 2018-01-05 珠海联邦制药股份有限公司 一种制备脂肪二酸衍生物的方法及其应用
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
TWI747929B (zh) 2016-08-02 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人胰島素或其類似物的醯化衍生物
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN111518009B (zh) * 2019-02-01 2023-06-23 鲁南制药集团股份有限公司 一种脂肪酸衍生物及其合成方法
WO2021185304A1 (zh) * 2020-03-18 2021-09-23 东莞市东阳光生物药研发有限公司 制备长脂肪链二酸衍生物的方法及其应用
CN114075275A (zh) * 2020-08-17 2022-02-22 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN116903512A (zh) * 2023-06-05 2023-10-20 浙江湃肽生物股份有限公司深圳分公司 一种德谷胰岛素中间体及其德谷胰岛素的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK45590D0 (da) 1990-02-21 1990-02-21 Novo Nordisk As
HU217684B (hu) 1993-09-17 2000-03-28 Novo Nordisk A/S Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
ES2230607T3 (es) * 1996-07-11 2005-05-01 Novo Nordisk A/S Metodo selectivo de acilacion.
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
DE69815877T2 (de) * 1997-10-24 2004-05-19 Novo Nordisk A/S Aggregate von menschlichen insulinderivaten

Also Published As

Publication number Publication date
RU2006103280A (ru) 2007-09-20
DK2107069T3 (da) 2013-04-15
RU2352581C2 (ru) 2009-04-20
ZA200600846B (en) 2007-04-25
EP2287184A3 (en) 2011-08-10
CN101955527A (zh) 2011-01-26
PT2275439E (pt) 2014-06-25
KR101186851B1 (ko) 2012-10-02
EP2264066A2 (en) 2010-12-22
EP2275439B1 (en) 2014-03-26
PL2275439T3 (pl) 2014-09-30
ES2402592T3 (es) 2013-05-07
CN1829738B (zh) 2012-07-04
EP2275439A2 (en) 2011-01-19
CN1829738A (zh) 2006-09-06
SI2107069T1 (sl) 2013-04-30
ES2472421T3 (es) 2014-07-01
PT2107069E (pt) 2013-04-23
EP2287184A2 (en) 2011-02-23
EP2264066A3 (en) 2011-07-27
EP2275439A3 (en) 2011-03-23
KR20120026629A (ko) 2012-03-19
CN101955527B (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
CY2013029I2 (el) Νεα παραγωγα ινσουλινης
CY2015036I2 (el) Νεα παραγωγα οξαζολιδινονης
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
NO20054136D0 (no) Imidazol-4-yl-etynyl-pyridin-derivater
ATE420066T1 (de) Amidoacetonitrilderivate
IS2656B (is) Nýjar besímídasólafleiður
DK2275439T3 (da) Hidtil ukendte insulinderivater
DK1531673T3 (da) Hidtil ukendt 2-pyridylethylbenzamidderivat
ATE352550T1 (de) Chinazolinderivate
DE602004013538D1 (de) Verbesserte messanordnung
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
IS8364A (is) N-þíasól-2-ýl-bensamíð afleiður
DE602004019555D1 (de) Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE449064T1 (de) Amidoacetonitrilderivate
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
FI20030666A0 (fi) Z-apukammiopalotila
IS8301A (is) Nýjar fúsíðsýruafleiður